PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| PTCT | PTC THERAPEUTICS, INC. | 2025-10-16 16:20:57 | 66.82 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PTCT | 0001070081 | PTC THERAPEUTICS, INC. | US69366J2006 | 549300UJLWOIWFDGB318 | 043416587 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 500 WARREN CORPORATE CENTER DRIVE | WARREN | NJ | 07059 | UNITED STATES | US | 9082227000 | 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059 | 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059 | PTC THERAPEUTICS INC | Pharmaceuticals | 1998-01-01 | — | — | http://ptcbio.com | 1,733,690,074 | 79,378,145 | 79,438,094 | PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases. | 2025-10-10 20:11:59 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 1,733,690,074 | -596,926,441 | -25.6124 | 78,869,368 | 2,261,338 | 2.9518 |
| 2023 | 2,330,616,515 | 201,084,121 | 9.4426 | 76,608,030 | 2,792,886 | 3.7836 |
| 2022 | 2,129,532,394 | -61,595,616 | -2.8111 | 73,815,144 | 2,452,673 | 3.4369 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Eric Pauwels | Chief Business Officer | 2024 | 570,217 | 0 | 624,267 | 436,900 | 25,056 | 2,398,470 |
| Lee Golden | Chief Medical Officer, Executive Vice President | 2024 | 548,333 | 0 | 580,594 | 421,000 | 23,538 | 2,248,039 |
| Matthew B. Klein | Chief Executive Officer | 2024 | 882,167 | 0 | 2,998,300 | 1,149,700 | 19,591 | 7,410,765 |
| Pierre Gravier | Chief Financial Officer | 2024 | 542,500 | 0 | 567,749 | 455,200 | 21,360 | 2,227,654 |
| Lee Golden | Chief Medical Officer, Executive Vice President | 2023 | 507,917 | 0 | 863,369 | 189,000 | 19,868 | 2,394,995 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 939 |
| 2023 | 995 |
| 2022 | 1,410 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 806,780,000 | 937,822,000 | 698,801,000 |
| Cost Of Revenue | 57,398,000 | 65,486,000 | 44,678,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 534,480,000 | 666,563,000 | 651,496,000 |
| General And Administrative Expenses | 300,911,000 | 332,540,000 | 325,998,000 |
| Operating Expenses | 1,109,350,000 | 1,377,324,000 | 1,146,210,000 |
| Operating Income | -302,570,000 | -439,502,000 | -447,409,000 |
| Net Income | -363,295,000 | -626,604,000 | -559,017,000 |
| Earnings Per Share Basic | -4.73 | -8.37 | -7.79 |
| Earnings Per Share Diluted | -4.73 | -8.37 | -7.79 |
| Weighted Average Shares Outstanding Basic | 76,845,055 | 74,838,392 | 71,728,634 |
| Weighted Average Shares Outstanding Diluted | 76,845,055 | 74,838,392 | 71,728,634 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 779,709,000 | 594,001,000 | 279,834,000 |
| Marketable Securities Current | 359,987,000 | 282,738,000 | 130,871,000 |
| Accounts Receivable | 158,554,000 | 160,822,000 | 155,614,000 |
| Inventories | 23,194,000 | 30,577,000 | 21,808,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 1,365,531,000 | 1,218,629,000 | 693,785,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 60,970,000 | 87,089,000 | 72,590,000 |
| Other Assets Non Current | 0 | 235,766,000 | 235,766,000 |
| Total Assets Non Current | 339,493,000 | 677,069,000 | 1,011,834,000 |
| Total Assets | 1,705,024,000 | 1,895,698,000 | 1,705,619,000 |
| Accounts Payable | 17,274,000 | 6,045,000 | 27,268,000 |
| Deferred Revenue | 5,505,000 | 801,000 | 1,351,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 4,701,000 | — | 4,712,000 |
| Total Liabilities Current | 580,981,000 | 603,100,000 | 406,236,000 |
| Long Term Debt | 285,412,000 | 284,213,000 | 571,722,000 |
| Other Liabilities Non Current | 21,426,000 | 141,000 | 2,641,000 |
| Total Liabilities Non Current | 2,222,114,000 | 2,111,153,000 | 1,646,469,000 |
| Total Liabilities | 2,803,095,000 | 2,714,253,000 | 2,052,705,000 |
| Common Stock | 77,000 | 75,000 | 72,000 |
| Retained Earnings | -3,646,873,000 | -3,283,578,000 | -2,656,974,000 |
| Accumulated Other Comprehensive Income | -25,886,000 | -1,285,000 | 4,796,000 |
| Total Shareholders Equity | -1,098,071,000 | -818,555,000 | -347,086,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 75,663,000 | 236,590,000 | 128,836,000 |
| Share Based Compensation Expense | 74,615,000 | 101,636,000 | 110,333,000 |
| Other Non Cash Income Expense | -4,298,000 | — | — |
| Change In Accounts Receivable | -1,732,000 | 1,539,000 | 48,468,000 |
| Change In Inventories | -6,164,000 | 8,183,000 | 6,668,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -33,322,000 | 48,346,000 | 27,542,000 |
| Change In Other Liabilities | 11,830,000 | -2,307,000 | -4,558,000 |
| Cash From Operating Activities | -107,688,000 | -158,418,000 | -356,654,000 |
| Purchases Of Marketable Securities | 59,377,000 | 38,398,000 | 22,787,000 |
| Sales Of Marketable Securities | 549,609,000 | 21,544,000 | 405,234,000 |
| Acquisition Of Property Plant And Equipment | 6,502,000 | 28,438,000 | 32,016,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 44,182,000 | -176,737,000 | 290,181,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 5,199,000 | 5,954,000 | 6,450,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 255,866,000 | 646,400,000 | 167,952,000 |
| Change In Cash | 185,032,000 | 314,359,000 | 98,707,000 |
| Cash At End Of Period | 779,709,000 | 594,001,000 | 279,834,000 |
| Income Taxes Paid | 17,550,000 | 14,155,000 | 4,922,000 |
| Interest Paid | 5,823,000 | 36,131,000 | 18,463,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -4.73 | -8.37 | -7.79 |
| Price To Earnings Ratio | -9.5433 | -3.2927 | -4.8999 |
| Earnings Growth Rate | -43.4886 | 7.4454 | 4.8452 |
| Price Earnings To Growth Ratio | 0.2194 | -0.4422 | -1.0113 |
| Book Value Per Share | -14.2894 | -10.9376 | -4.8389 |
| Price To Book Ratio | -3.159 | -2.5197 | -7.8882 |
| Ebitda | -264,565,000 | -344,959,000 | -418,900,000 |
| Enterprise Value | 2,974,488,782.7 | 1,752,758,083.52 | 3,029,769,959.78 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | -0.2599 | -0.3472 | -1.6472 |
| Capital Expenditures | 49,544,000 | 251,089,000 | 148,841,000 |
| Free Cash Flow | -157,232,000 | -409,507,000 | -505,495,000 |
| Return On Equity | 0.3308 | 0.7655 | 1.6106 |
| One Year Beta | 1.3718 | 1.3462 | 0.862 |
| Three Year Beta | 1.0338 | 0.9075 | 0.9297 |
| Five Year Beta | 0.992 | 0.9989 | 1.0183 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Boulding Mark Elliott | EXEC. VP AND CLO | 2025-10-07 | 3,375 | A | 107,276 |
| Boulding Mark Elliott | EXEC. VP AND CLO | 2025-10-07 | 1,757 | D | 105,519 |
| Boulding Mark Elliott | EXEC. VP AND CLO | 2025-10-07 | 1,306 | D | 104,213 |
| Boulding Mark Elliott | EXEC. VP AND CLO | 2025-10-07 | 312 | D | 103,901 |
| Boulding Mark Elliott | EXEC. VP AND CLO | 2025-10-07 | 3,375 | D | 3,376 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| CWM, LLC | 2025-09-30 | 1,053,000 | 17,163 | 61.3529 |
| Pacer Advisors, Inc. | 2025-09-30 | 30,928,393 | 503,966 | 61.37 |
| Inspire Investing, LLC | 2025-09-30 | 461,430 | 7,519 | 61.3685 |
| HARBOR CAPITAL ADVISORS, INC. | 2025-09-30 | 3,044,000 | 49,600 | 61.371 |
| Vontobel Holding Ltd. | 2025-09-30 | 467,639 | 7,620 | 61.3699 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| TRUST FOR PROFESSIONAL MANAGERS | 2025-08-31 | Column Small Cap Select Fund | CFSSX | 37,952 | 1,872,172.16 | 0.1303 |
| Pacer Funds Trust | 2025-07-31 | Pacer US Small Cap Cash Cows ETF | CALF | 704,105 | 36,690,911.55 | 0.9168 |
| ETFis Series Trust I | 2025-07-31 | Virtus LifeSci Biotech Products ETF | BBP | 8,717 | 454,242.87 | 1.8431 |
| Advisors' Inner Circle Fund III | 2025-07-31 | I Shares | KCXIX | 348 | 18,134.28 | 0.0075 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2025-07-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 51,528 | 2,685,124.08 | 0.1133 |